Does Blue Cross Blue Shield of Michigan Cover Wegovy?
The verdict
Not Covered on most plans
Blue Cross Blue Shield of Michigan ended weight-loss GLP-1 coverage on fully insured large-group plans effective January 1, 2025, citing GLP-1 costs that grew from roughly $8 million to nearly $200 million over three years. This is a benefit exclusion — PA will not succeed on affected plans. Exceptions: self-funded employer groups that opted in, Michigan Medicaid (which covers Wegovy as a preferred anti-obesity medication with PA and quantity limits for ages 12 and older), and Medicare (cardiovascular indication only).
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Blue Cross Blue Shield of Michigan using your member ID.
Key facts
BCBS of Michigan's GLP-1 drug spending grew from approximately $8 million to nearly $200 million over roughly three years — the cost rationale behind its January 1, 2025 weight-loss GLP-1 exclusion for fully insured large-group plans.
BCBS of Michigan communications, 2024
Michigan Medicaid covers Wegovy as a preferred anti-obesity medication with prior authorization and quantity limits for members age 12 and older — an exception to the BCBS-MI commercial exclusion.
Michigan Medicaid preferred drug list
The Medicare GLP-1 Bridge launches July 1, 2026, giving eligible Medicare beneficiaries Wegovy weight-loss access at $50/month outside Part D — not counting toward the $2,100 OOP cap.
CMS.gov, Medicare GLP-1 Weight Loss Drug Access Program
Medicare vs. commercial coverage
Whether Blue Cross Blue Shield of Michigan covers Wegovy depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Medicare Part D cannot cover Wegovy for weight loss by statute — this applies to all BCBS-MI Medicare plans. BCBS-MI Medicare Advantage plans can cover Wegovy for the cardiovascular risk-reduction indication (FDA-approved for adults with established CVD who are overweight or obese) with prior authorization. The Medicare GLP-1 Bridge launches July 1, 2026, giving eligible Medicare beneficiaries weight-loss access to Wegovy at $50/month through December 31, 2027 — this operates outside Part D, so the $50 does not count toward the $2,100 OOP cap or TrOOP. Extra Help cannot be applied to Bridge copays. NovoCare savings card is not available to Medicare beneficiaries.
Commercial / Employer
Group & marketplace plans
BCBS of Michigan ended weight-loss GLP-1 coverage on fully insured large-group plans effective January 1, 2025. The stated reason: GLP-1 drug spending grew from approximately $8 million to nearly $200 million over roughly three years — the cost became unsustainable under the fully insured model. This is a benefit exclusion: no prior authorization will override it on an excluded fully insured plan, and a medical-necessity appeal will not succeed where the drug is categorically excluded from covered benefits. Self-funded employer groups are a separate matter — some chose to retain weight-loss GLP-1 coverage or can elect to add it; ask HR whether your specific plan is fully insured (excluded) or self-funded (may still include coverage). ACA/individual-market plans generally exclude Wegovy for weight loss. NovoCare savings card ($25/month, max $100/28-day supply) is available only where the plan covers Wegovy — not applicable to the excluded fully insured weight-loss use. NovoCare savings card is not available to Medicare or Medicaid beneficiaries.
Your cost, three ways
What Wegovy actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
$1,349/month (Novo Nordisk published list price for a 28-day supply) — the default for fully insured large-group members where weight-loss GLP-1 coverage ended. NovoCare self-pay: approximately $349/month for standard injection doses after an introductory period through December 31, 2026.
List price with no coverage — before any manufacturer savings card.
With coverage
Not applicable for weight-loss use on fully insured large-group plans (coverage ended 1/1/2025). Michigan Medicaid: nominal cost-share where covered as preferred AOM. Self-funded groups that opted in: specialty-tier cost-share varies by plan. NovoCare savings card ($25/month, max $100/28-day supply) available to commercially insured members whose plan covers Wegovy — not applicable to excluded fully insured weight-loss use; not available to Medicare or Medicaid.
Typical monthly copay once prior authorization is approved.
Bridge program
Medicare GLP-1 Bridge: $50/month fixed copay for eligible Medicare beneficiaries, launching July 1, 2026, through December 31, 2027. Operates outside Part D — does not count toward the $2,100 OOP cap, TrOOP, or Extra Help. Provider must attest eligibility at initiation.
Reduced copay through the assistance program, where eligible.
All cost figures are estimates. Actual cost-share varies by plan and pharmacy — confirm with your BCBS-MI plan and pharmacist before starting treatment.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Confirm whether your plan is fully insured or self-funded
Ask your HR benefits team whether your employer plan is fully insured or self-funded. Fully insured large-group BCBS-MI plans excluded weight-loss GLP-1s effective January 1, 2025 — that exclusion cannot be overridden by PA. Self-funded groups may have retained or added the benefit. This is the single most important step for BCBS-MI members.
- 2
If on Michigan Medicaid, check the BCBS-MI Medicaid formulary
Michigan Medicaid covers Wegovy as a preferred anti-obesity medication with prior authorization and quantity limits for ages 12 and older. BCBS-MI administers Medicaid managed-care plans in Michigan — verify current status on the MI Medicaid preferred drug list or BCBS-MI Medicaid member services.
- 3
Ask your prescriber about the cardiovascular indication or Medicare Bridge
If you have established cardiovascular disease (prior heart attack, stroke, or symptomatic PAD) and are overweight or obese, the Wegovy CV indication may be coverable with PA even on excluded commercial plans. From July 1, 2026, eligible Medicare beneficiaries can access Wegovy for weight loss via the Bridge at $50/month. Discuss with your prescriber.
Options if Blue Cross Blue Shield of Michigan won't cover Wegovy
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Michigan Medicaid preferred AOM coverage
Michigan Medicaid covers Wegovy as a preferred anti-obesity medication for eligible members age 12 and older with prior authorization and quantity limits — unlike the BCBS-MI fully insured commercial exclusion. If you are a BCBS-MI Medicaid managed-care member, this is an important exception to the commercial coverage story.
NovoCare self-pay program
Novo Nordisk's NovoCare Pharmacy offers Wegovy at approximately $349/month for patients without coverage. An introductory rate of approximately $199/month applies to the 0.25 and 0.5 mg doses through December 31, 2026. List price is announced to drop to approximately $675/month effective January 1, 2027.
Compounded semaglutide
Compounded semaglutide is available without insurance for patients who cannot access covered Wegovy. See the Curex offer below. Compounded medications are not the same as Wegovy and have not been approved by the FDA.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
No, for most members. BCBS of Michigan ended weight-loss GLP-1 coverage on fully insured large-group plans effective January 1, 2025, after GLP-1 spending grew from roughly $8 million to nearly $200 million. This is a benefit exclusion — no PA will reverse it on an affected plan. Exceptions: self-funded employer groups that retained the benefit (ask HR whether your plan is self-funded), Michigan Medicaid (covers Wegovy as a preferred AOM with PA/QL), and Medicare (CV indication only). Verify your plan type before assuming either outcome.
Blue Cross Blue Shield of Michigan cited unsustainable cost growth: GLP-1 drug spending rose from approximately $8 million to nearly $200 million over roughly three years. At that trajectory, fully insured large-group plans could not sustain coverage without major premium increases. The decision to exclude weight-loss GLP-1s effective January 1, 2025 was a cost-management measure — the same financial pressure driving several other large Blue plans to restrict anti-obesity drug access in 2024 and 2025.
Yes. Michigan Medicaid covers Wegovy as a preferred anti-obesity medication with prior authorization and quantity limits for members age 12 and older — this is a notable exception to the BCBS-MI commercial exclusion. BCBS of Michigan administers Medicaid managed-care plans in the state. If you are on a BCBS-MI Medicaid plan and meet the BMI and clinical criteria, your prescriber can submit a PA for Wegovy under the preferred AOM benefit. Verify current MI Medicaid PDL status with BCBS-MI Medicaid member services.
Both ended weight-loss GLP-1 coverage effective January 1, 2025, but the scope differs. Independence Blue Cross excluded weight-loss GLP-1s across all fully insured group and individual plans, including ACA plans. BCBS-MI's exclusion was specifically for fully insured large-group commercial plans — self-funded employer groups may opt in, and Michigan Medicaid (not available to Independence's Philadelphia-market members) retains Wegovy as a preferred AOM. For pure commercial weight-loss seekers, both plans are a hard no on the fully insured side.
Yes, potentially. The January 1, 2025 exclusion applies to fully insured large-group plans — where BCBS-MI bears the insurance risk. Self-funded employer groups, where the employer bears the risk and BCBS-MI is only the administrator, can choose their own benefit design. Some self-funded employers chose to retain weight-loss GLP-1 coverage after the 2025 change. Ask your HR benefits team whether your plan is self-funded, and if so, whether anti-obesity medications are included. This is the one commercial exception to the general no.
Related Articles
Does BCBS North Carolina Cover Wegovy? 2026 | Curex
BCBS North Carolina: NC State Health Plan dropped weight-loss GLP-1s in 2024; NC Medicaid removed obesity coverage October 2025. Verify your specific plan.
Read moreDoes BCBS of Arizona Cover Wegovy? 2026 Guide | Curex
BCBS of Arizona covers Wegovy only where your employer opted in; formulary not published. Verify via drug-lookup and confirm with HR first.
Read moreDoes Blue Cross Blue Shield of Illinois Cover Wegovy? | Curex
BCBS Illinois (HCSC) covers Wegovy only where your employer opts in. ACA plans exclude it. Formulary not public — verify on your plan's drug-lookup tool.
Read moreDoes BCBS Alabama Cover Wegovy? 2026 Guide | Curex
BCBS Alabama Wegovy coverage is employer-dependent and unpublished. Alabama Medicaid excludes obesity GLP-1s. How to verify your specific plan.
Read moreDoes Blue Cross Blue Shield of Texas Cover Wegovy? | Curex
BCBS Texas (HCSC) covers Wegovy only where your employer opts in. ACA and Texas Medicaid exclude it. Formulary not public — verify on your plan.
Read moreDoes Blue Cross MN Cover Wegovy? 2026 Employer Guide | Curex
Blue Cross MN covers Wegovy only where your employer bought the anti-obesity benefit. Not published at drug level — check plan drug lookup and ask HR.
Read moreWhether or not Blue Cross Blue Shield of Michigan covers Wegovy, there's a path that skips insurance
BCBS of Michigan ended fully insured large-group weight-loss GLP-1 coverage in 2025. For patients facing that exclusion, Curex offers compounded semaglutide from $49/mo (compounded tirzepatide from $149/mo) at getcurex.com/cl/glp — no insurance, no prior authorization. Compounded semaglutide is not the same medication as Wegovy. Prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Wegovy and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Blue Cross Blue Shield of Michigan before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Wegovy and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.